Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
15-Month Randomized Double-Blind Placebo-Controlled Trial of LMTM in Mild to Moderate Alzheimer's Disease
2012-002866-11Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromethylthionine mesylate in Alzheimer's disease (AD) (4 arms), sponsored by TauRx Therapeutics Ltd. Primary endpoints: ADAS-cog11 and ADCS-CGIC. Started Nov 2012; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-002866-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002866-11.